About this trial
Mitral regurgitation (MR) is the most prevalent valvular heart disease in China. Transcatheter edge-to-edge repair (TEER) is currently the preferred treatment for patients with severe MR who face high surgical risks. However, existing preoperative assessment methods for TEER suffer from numerous limitations, including complex measurement parameters, high technical demands, and significant subjectivity. Vision Mamba, a cutting-edge technology in the visual domain, overcomes the limitations of common computational units in convolutional neural networks and Transformers through bidirectional state space models and positional encoding, demonstrating exceptional performance in visual tasks. To date, no studies have applied Vision Mamba to ultrasound videos for constructing TEER preoperative assessment models. Our team previously established a Transformer-based evaluation model using a small, single-center cohort. This study innovatively introduces a Vision Mamba-based visual foundation model. By integrating multi-faceted, multi-modal ultrasound videos from multiple centers, we develop a one-stop preoperative TEER assessment model for MR patients \[slice identification → video analysis → multi-modal information fusion → preoperative assessment recommendation (suitable/challenging/unsuitable)\]. This model will optimize surgical patient identification and accurately screen patients with contraindications. Furthermore, the one-stop model is fast and objective, significantly improving clinical efficiency. It holds promise for deployment at primary care levels to optimize healthcare resource allocation.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age: 18-90 years
Patients with moderate to severe or severe mitral regurgitation as indicated by echocardiography
Disqualifiers
Moderate or severe aortic stenosis or aortic regurgitation, or following aortic valve replacement
Patients with congenital heart disease
Poor image quality: Insufficient cross-sectional coverage or inability to perform effective mitral valve marking
Trial population
The study population was drawn from Beijing Hospital and Fuwai Hospital of the Chinese Academy of Medical Sciences.
Trial design
Other
Prospective
Treatments tested in this trial
Model Construction, Validation, and Optimization
Other interventionData from patients in this study will be used for model construction, validation, and optimization.
Treatment groups
Trial outcomes
Primary outcomes
Echocardiography-related indicators
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: